First off it randomized, placebo controlled, and double blinded. It also appears to be properly powered to actually show statistical significance. There are multiple arms so that dose dependent response can be identified and quantified and compared to the actual placebo response from patients who experienced the exact same conditions as those receiving Bryostatin. The primary outcome is efficacy as measured by SIB scores. The weakness is that the trial duration is shorter than optimal to prove long term efficacy.
I think the tweet has the situation evaluated correctly.
News 
Market Data 
Discover 
